TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12453280
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Study: 12453280
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Study: 10357743
Drug: Calcium glycerophosphate-supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium glycerophosphate-supplemented infant formula (1800 mg Ca and 1390 mg P/L)
Study: 10357743
Drug: Iron-fortified infant
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified infant formula (465 mg Ca and 317 mg P/L)
Study: 2166429
Drug: Ketoconazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (600 mg/day for 28 days)
Study: 2166429
Drug: Pentostam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentostam (20 mg antimony/kg for 20 days)
Study: 7197583
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2/week
Study: 31565909
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation with individualized dosing to achieve 25(OH)D of 120 nmol/L for 8 weeks
Study: 31210099
Drug: Ciclosporin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (initial loading dose of 2.5 mg/kg followed by continuous infusion for 5 days; first 10 patients received 5 mg/kg/day, subsequent 6 patients received 10 mg/kg/day)
Study: 11583199
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg per day during conventional-dose TIP and two doses of 500 mg during high-dose CET)
Study: 7990309
Drug: Endobronchial application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial application of a helium-neon laser beam in combination with traditional methods in the preoperative period
Study: 25976288
Drug: Control (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (six weekly sessions of behavioural support for smoking cessation)
Study: 8156739
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g body weight/kg)
Study: 8156739
Drug: Ethanol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.0 g body weight/kg)
Study: 3345153
Drug: 0.5% ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ketorolac tromethamine solution
Study: 29222647
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg every 3 weeks plus chemotherapy (cisplatin 50 mg/m2 or carboplatin AUC 5 plus paclitaxel 175 mg/m2 for 6-8 cycles)
Study: 21915047
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL)
Study: 21915047
Drug: Topical antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antihistamine (antazoline HCl 0.05%) and vasoconstrictor (tetrahydrozoline HCl 0.04%)
Study: 12869833
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI)-based regimen
Study: 10516747
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2 on days 1, 8, 15, and 22 for induction; 20 mg/m2 for 4 weeks for consolidation; maintenance with oral 6 mercaptopurine 2 mg/kg/day, subcutaneous cytarabine 1 mg/kg, and oral ZVD 20 mg/m2 on day 1 and day 8 of the third month.
Study: 10516747
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment with 4 weekly oral doses of 40 mg/m2 ZVD after induction failure.
Study: 10516747
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2.
Study: 14607696
Drug: Endoscopic retrograde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic retrograde cholangiopancreatography (ERCP) within 24 hours after admission, combined with supportive treatment and traditional Chinese medicine.
Study: 14607696
Drug: Non-ERCP treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ERCP treatment, combined with supportive treatment and traditional Chinese medicine.
Study: 14607696
Drug: ERCP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERCP treatment in mild acute GP patients.
Study: 3658278
Drug: Cefazolin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1-g dose)
Study: 3658278
Drug: Cefonicid (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1-g dose)
Study: 29780106
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of oral medications
Study: 29780106
Drug: Drug burden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug burden comparison
Study: 17075122
Drug: Bortezomib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.5 mg/m2 (arm A)
Study: 11185632
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg three times daily
Study: 9457396
Drug: DLI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLI plus low-dose rIL-2
Study: 9457396
Drug: High-dose rIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rIL-2
Study: 9457396
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rIL-2 and IFN-alpha
Study: 7897617
Drug: Amisulpride 20
Normalized name: amisulpride 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 20 mg
Study: 9226734
Drug: Amisulpride 100
Normalized name: amisulpride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 100 mg
Study: 3310792
Drug: Air-fluidized beds
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-fluidized beds (Clinitron Therapy)
Study: 31765277
Drug: Technology-enhanced reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-enhanced reading therapy (14 hours)
Study: 31765277
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed therapy)
Study: 29855167
Drug: Supraciliary implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraciliary implantation of hema implant (Esnoper V-2000)
Study: 29855167
Drug: Intrascleral implantation
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrascleral implantation of hema implant (Esnoper V-2000)
Study: 26579985
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (first-line therapy failure).
Study: 11360565
Drug: Traditional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional medicine Syndrome Differentiation
Study: 15957828
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine alone
Study: 27083449
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch for 6 weeks
Study: 20378736
Drug: MDMA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.6 mg/kg)
Study: 10458207
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with gemcitabine
Study: 10458207
Drug: Docetaxel within
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel within a sequential and concomitant chemoradiotherapy concept
Study: 2037789
Drug: B subunit
Normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit (BS)‐whole‐cell vaccine
Study: 19842576
Drug: Treatment modalities
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modalities for psoriasis (exact treatments not specified) for 15 participants over 16 weeks followed by 12 weeks of observation.
Study: 15521902
Drug: Methadone 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 5‐20 mg 12 hourly
Study: 15521902
Drug: Tincture of
Normalized name: Tincture of opium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of opium (TOP) 3.33‐10 mg morphine equivalents 12 hourly
Study: 8839906
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tropisetron
Study: 12183788
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tropisetron
Study: 7839305
Drug: Control (motility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (motility modifying drugs)
Study: 356971
Drug: Combination or
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone
Study: 23452506
Drug: Adherence Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence Therapy (AT)
Study: 18997461
Drug: TFA-enriched diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFA-enriched diet (10.4 g TFAs for 4 days)
Study: 18997461
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet (0.8 g TFAs)
Study: 16014054
Drug: High CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CRP (≥3.0 mg/L)
Study: 1341478
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with corticoids (40 mg/day for 2 weeks, then 20 mg/day for 2 weeks) followed by interferon-alpha (2 MU, 3 times a week for 3 months)
Study: 26765505
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care protocol (tooth brushing, tongue scraping, flossing, mouth rinsing, lip care)
Study: 31572763
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care protocol
Study: 18827631
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion pump with Bupivacaine (0.375%)
Study: 10919936
Drug: Salt-restricted diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt-restricted diet (<5 g/d sodium chloride)
Study: 8670579
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 250 mg monthly injections
Study: 1522491
Drug: Sustained-release hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release hydralazine without KCl
Study: 30753272
Drug: cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib 30 mg daily and olaparib capsules 200 mg twice daily
Study: 30753272
Drug: olaparib capsules
Normalized name: Olaparib Capsules
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: olaparib capsules 400 mg twice daily
Study: 30753272
Drug: cediranib/olaparib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib/olaparib combination in gBRCA wild-type/unknown patients
Study: 30753272
Drug: cediranib/olaparib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib/olaparib combination in gBRCAm patients
Study: 29428785
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid supplements
Study: 17255882
Drug: HES 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4 (Group H, 45 g/d), HES 130/0.4 (Group M, 30 g/d), HES 130/0.4 (Group L, 15 g/d)
Study: 17255882
Drug: Glucose 5%
Normalized name: Glucose 5% Nursette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 5% (Group G)
Study: 12141616
Drug: Current smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current smoking (25 or more cigarettes daily)
Study: 31653221
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and subsequent long-term oral tranexamic acid (TXA)
Study: 31653221
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral 1 g from POD 1 to POD 14)
Study: 29374249
Drug: Monthly vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly vitamin D3 50,000 IU orally monthly plus three placebo tablets 3-monthly
Study: 29374249
Drug: 3-monthly vitamin
Normalized name: Vitamin K 3
DrugBank: Menadione (DB00170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-monthly vitamin D3 150,000 IU (3 × 50,000 IU tablets) 3-monthly and placebo orally monthly
Study: 10840005
Drug: Platelet glycoprotein
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin (eptifibatide) Therapy
Study: 1609767
Drug: Olestra (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (20 g fat replacement)
Study: 1609767
Drug: Olestra (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (0 g fat replacement)
Study: 31926554
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - TFLM protected by an autogenous tissue 'pad' from the anterior capsule of the joint.
Study: 30017831
Drug: Nedaplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin (80 mg/m2) plus Docetaxel (75 mg/m2)
Study: 30017831
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) plus Docetaxel (75 mg/m2)
Study: 21629990
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg q2w) plus Cetuximab (400/250 mg/m(2) initial/weekly) with Gemcitabine (1000 mg/m(2) weekly × 3 of 4 weeks)
Study: 21629990
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg q2w) plus Cetuximab (400/250 mg/m(2) initial/weekly) without Gemcitabine
Study: 20860915
Drug: Risperidone 1
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1 mg Mouth dissolving tablet, Ranbaxy (test product)
Study: 20860915
Drug: Risperdal 1
Normalized name: Risperdal 1mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperdal 1 mg Quicklet (reference product)
Study: 10924844
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day, n=15)
Study: 8199723
Drug: Metoprolol 50-200
Normalized name: metoprolol tartrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50-200 mg daily
Study: 8199723
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Felodipine and Metoprolol
Study: 3328329
Drug: Chlorproguanil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil (20 mg base weekly)
Study: 3328329
Drug: Chloroquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (200 mg base weekly)
Study: 31699660
Drug: Rivaroxaban (20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20-mg equivalent dose, bodyweight-adjusted)
Study: 31699660
Drug: Standard anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulants (heparin or switched to vitamin K antagonist)
Study: 25312637
Drug: Bivalirudin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin monotherapy
Study: 15531680
Drug: MM supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM supplements (vitamins A, B complex, C, D, E, and K and iron, zinc, and magnesium; 6 d/wk for 12 wk)
Study: 11172190
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (100 U) after initial placebo treatment
Study: 23706
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dimethpyrindene (0.1 mg/kg b.w.) and cimetidine (10 mg/kg b.w.)
Study: 25473216
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheet
Study: 29798375
Drug: Post-auricular subperiosteal
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-auricular subperiosteal injection of methylprednisolone (40 mg/ml)
Study: 14555500
Drug: Fulvestrant (FVT)
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant (FVT) 250 mg i.m. monthly
Study: 14555500
Drug: Anastrozole (ANZ)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole (ANZ) 1 mg p.o. daily
Study: 1978871
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled bronchodilator treatment (fenoterol)
Study: 6772381
Drug: Tocainide (17.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (17.7 +/- 4.9 mg/kg/day)
Study: 17956584
Drug: 10% IVIg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% IVIg ready‐to‐use solution
Study: 17956584
Drug: 6% IVIg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% IVIg lyophilized solution
Study: 10217585
Drug: Calcitriol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (1.0 microg) coadministered with influenza vaccine
Study: 7574828
Drug: Sunscreen plus
Normalized name: Sunmark Sunscreen Plus E and Aloe SPF 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen plus UVB (SPF 29 sunscreen containing octyl methoxycinnamate, oxybenzone, and octyl salicylate) followed by three minimal erythema doses of UVB irradiation.
Study: 7574828
Drug: UVB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB group (three minimal erythema doses of UVB irradiation without sunscreen).
Study: 2710641
Drug: Carbamazepine divitabs
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine divitabs (sustained-release formulation)
Study: 2710641
Drug: Carbamazepine normal
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine normal formulation (ordinary tablets)
Study: 7015139
Drug: Tamoxifen combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen combined with L‐phenylalanine mustard and 5‐fluorouracil
Study: 31522806
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine with 85% efficacy
Study: 31522806
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine with 50% efficacy
Study: 31522806
Drug: Vaccine-related social
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-related social concerns
Study: 7653319
Drug: Behavioral marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral marital therapy (BMT) with relapse prevention (RP)
Study: 7653319
Drug: Behavioral marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral marital therapy (BMT) without relapse prevention (RP)
Study: 20837791
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection
Study: 8091463
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) at 1 g per kg per day for 2 consecutive days each week for 4 weeks
Study: 8091463
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline placebo administered according to the same schedule as IVIG
Study: 29759857
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of IV‐TXA at 3‐hour intervals (group C)
Study: 21146270
Drug: eGFR ≥75
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR ≥75 mL/min/1.73 m(2)
Study: 21146270
Drug: eGFR <30
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <30 mL/min/1.73 m(2) and dipstick-positive proteinuria
Study: 16479736
Drug: Personalized asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalized asthma desensitization (previously specific immunotherapy, SIT)
Study: 16479736
Drug: Usual medications
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medications (control group)
Study: 12207596
Drug: Intermittent fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent fluticasone propionate (FP) cream 0.05% (twice per week)
Study: 8567611
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy adapted for sexually abused preschool children (CBT-SAP)
Study: 9291724
Drug: Nondirective supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondirective supportive therapy (NST)
Study: 1858672
Drug: Bepridil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (200 to 400 mg/day)
Study: 22251061
Drug: Traditional liquid
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional liquid spray pump (Spray)
Study: 16438474
Drug: Ropinirole (0.25-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.25-4.0 mg once daily, 1 to 3 hours before bedtime)
Study: 1408294
Drug: Morphine by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine by PKPCA
Study: 1785361
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (low-salt diet 70 to 90 mEq of Na per day, stopping diuretics and laxatives, elastic stockings) + carbidopa/levodopa 25/100 (3 tabs/day) + captopril 6.25 mg q 8 h
Study: 30975143
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg, twice daily for 12 months)